Komori
Tdk (6762) · FactFull-year R&D expenses and ratio updated

R&D expenses as a percentage of revenue: 7.8%

First written in FY2017-Q1. . Latest entry: FY2026.

34entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q1 – FY20262016: 220162017: 420172018: 420182019: 420192020: 320202021: 420212022: 420222023: 320232024: 320242025: 220252026: 12026
Same theme, other companies
Ongoing disclosure of the R&D expense-to-sales ratioA theme 1 companies write about · 0 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥289,668 million, up 14.2% from the previous fiscal year and equivalent to 11.6% of net sales.」

    R&D expenses increased from ¥253,586 million in the previous fiscal year to ¥289,668 million, while the ratio to net sales rose from 11.5% to 11.6%.
  2. FY2026-H1Updated interim-period R&D expenses and ratioAnnual report

    「R&D expenses for the interim consolidated accounting period were ¥133,785 million, equivalent to 11.3% of net sales.」

    Interim-period R&D expenses were ¥133,785 million, up from ¥123,186 million in the same period of the previous year, while the ratio was unchanged.
  3. FY2025Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥253,586 million, up 34.3% from the previous fiscal year and equivalent to 11.5% of net sales.」

    R&D expenses were ¥253,586 million, equivalent to 11.5% of net sales, up 34.3% from the previous fiscal year.
  4. FY2025-H1Updated interim-period R&D expenses and ratioAnnual report

    「R&D expenses for the interim consolidated accounting period were ¥123,186 million, equivalent to 11.3% of net sales. There were no material changes in the status of R&D activities.」

    Interim-period R&D expenses were ¥123,186 million, equivalent to 11.3% of net sales. No material changes in the status of R&D activities were reported.
  5. FY2024Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥188,860 million, up 5.2% from the previous fiscal year and equivalent to 9.0% of net sales.」

    Full-year R&D expenses were ¥188,860 million, equivalent to 9.0% of net sales, up 5.2% from the previous fiscal year.
  6. FY2024-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥138,577 million, equivalent to 8.6% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥138,577 million, equivalent to 8.6% of net sales, and no material changes in the status of R&D activities were reported.
  7. FY2024-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥90,106 million, equivalent to 8.5% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥90,106 million, equivalent to 8.5% of net sales, and no material changes in the status of R&D activities were reported.
  8. FY2024-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥43,905 million, equivalent to 8.7% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative first-quarter R&D expenses were ¥43,905 million, equivalent to 8.7% of net sales. No material changes in the status of R&D activities were reported.
  9. FY2023-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥134,589 million, equivalent to 7.9% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥134,589 million, equivalent to 7.9% of net sales.
  10. FY2023-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥89,550 million, equivalent to 8.0% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥89,550 million, equivalent to 8.0% of net sales. No material changes in the status of R&D activities were reported.
  11. FY2023-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥44,513 million, equivalent to 8.7% of net sales. There were no material changes in the status of R&D activities.」

    First-quarter R&D expenses were ¥44,513 million, equivalent to 8.7% of net sales, and no material changes in the status of R&D activities were reported.
  12. FY2022Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥165,250 million, up 29.7% from the previous fiscal year and equivalent to 8.7% of net sales.」

    Full-year R&D expenses were ¥165,250 million, equivalent to 8.7% of net sales, up 29.7% from the previous fiscal year.
  13. FY2022-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥120,709 million, equivalent to 8.7% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥120,709 million, equivalent to 8.7% of net sales. No material changes in the content of R&D activities were reported.
  14. FY2022-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥79,143 million, equivalent to 8.9% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥79,143 million, equivalent to 8.9% of net sales. No material changes in the status of R&D activities were reported.
  15. FY2022-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥37,680 million, equivalent to 9.0% of net sales. There were no material changes in the status of R&D activities.」

    First-quarter R&D expenses were ¥37,680 million, equivalent to 9.0% of net sales, and no material changes in the status of R&D activities were reported.
  16. FY2021Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥127,046 million, up 8.1% from the previous fiscal year and equivalent to 8.6% of net sales.」

    Full-year R&D expenses were ¥127,046 million, equivalent to 8.6% of net sales, up from the previous fiscal year.
  17. FY2021-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥92,378 million, equivalent to 8.5% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥92,378 million, equivalent to 8.5% of net sales.
  18. FY2021-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥59,818 million, equivalent to 8.7% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥59,818 million, equivalent to 8.7% of net sales, with the ratio up from 8.2% in the same period of the previous year.
  19. FY2021-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥29,434 million, equivalent to 9.5% of net sales. There were no material changes in the status of R&D activities.」

    First-quarter R&D expenses were ¥29,434 million, equivalent to 9.5% of net sales, with the ratio up from 8.5% in the same period of the previous year.
  20. FY2020-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥88,632 million, equivalent to 8.3% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥88,632 million, equivalent to 8.3% of net sales. No material changes in the status of R&D activities were reported.
  21. FY2020-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥58,265 million, equivalent to 8.2% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥58,265 million, equivalent to 8.2% of net sales, and no material changes in the status of R&D activities were reported.
  22. FY2020-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥28,584 million, equivalent to 8.5% of net sales. There were no material changes in the status of R&D activities.」

    First-quarter R&D expenses were ¥28,584 million, equivalent to 8.5% of net sales.
  23. FY2019Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥115,155 million, up 12.2% from the previous fiscal year and equivalent to 8.3% of net sales.」

    R&D expenses were ¥115,155 million, equivalent to 8.3% of net sales, up from the previous fiscal year.
  24. FY2019-Q3Updated cumulative third-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥86,871 million, equivalent to 8.1% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥86,871 million, equivalent to 8.1% of net sales. No material changes in the status of R&D activities were reported.
  25. FY2019-Q2Updated cumulative second-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥57,429 million, equivalent to 8.0% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥57,429 million, equivalent to 8.0% of net sales.
  26. FY2019-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥27,741 million, equivalent to 8.1% of net sales. There were no material changes in the status of R&D activities.」

    R&D expenses for the current first quarter were ¥27,741 million, equivalent to 8.1% of net sales, and no material changes in the status of R&D activities were reported.
  27. FY2018Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥103,457 million, up 13.4% from the previous fiscal year and equivalent to 8.1% of net sales.」

    Full-year R&D expenses were ¥103,457 million, equivalent to 8.1% of net sales, up 13.4% year on year.
  28. FY2018-Q3Updated cumulative R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥75,945 million, equivalent to 7.9% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥75,945 million, equivalent to 7.9% of net sales, and no material changes in R&D activities were reported.
  29. FY2018-Q2Updated cumulative R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥48,938 million, equivalent to 7.8% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥48,938 million, equivalent to 7.8% of net sales, and no material changes in R&D activities were reported.
  30. FY2018-Q1Updated first-quarter R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative first-quarter period were ¥22,720 million, equivalent to 7.8% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative first-quarter R&D expenses were ¥22,720 million, equivalent to 7.8% of net sales, and no material changes in R&D activities were reported.
  31. FY2017Full-year R&D expenses and ratio updatedAnnual report

    「R&D expenses for the fiscal year were ¥91,254 million, up 7.5% from the previous fiscal year and equivalent to 7.7% of net sales.」

    Full-year R&D expenses were ¥91,254 million, equivalent to 7.7% of net sales.
  32. FY2017-Q3Updated cumulative R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative third-quarter period were ¥68,272 million, equivalent to 7.6% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative third-quarter R&D expenses were ¥68,272 million, equivalent to 7.6% of net sales, and no material changes in the activities were reported.
  33. FY2017-Q2Updated cumulative R&D expenses and ratioAnnual report

    「R&D expenses for the cumulative second-quarter period were ¥43,767 million, equivalent to 7.6% of net sales. There were no material changes in the status of R&D activities.」

    Cumulative second-quarter R&D expenses were ¥43,767 million, equivalent to 7.6% of net sales, and no material changes in the activities were reported.
  34. FY2017-Q1First statedAnnual report

    「R&D expenses for the cumulative first quarter were ¥21,634 million, representing 7.8% of revenue. There were no material changes in R&D activities.」

    Discloses R&D expenses and the ratio to net sales for the current first quarter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Tdk's next results are scheduled for 2026-10-30. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.